S168: PELABRESIB (CPI-0610) MONOTHERAPY IN PATIENTS WITH HIGH-RISK ESSENTIAL THROMBOCYTHEMIA REFRACTORY OR INTOLERANT TO HYDROXYUREA: PRELIMINARY RESULTS FROM MANIFEST STUDY
HemaSphere | August 8, 2023 | Volume: 7 | Issue: S3 | Pages: e9927843
10.1097/01.hs9.0000967584.99278.43